XERS Xeris Biopharma Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1867096 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.4%
TTM net income YoY58.5%
TTM EPS YoY70.0%
Revenue 3-yr CAGR34.1%
Net income 3-yr CAGR—
Margins
Gross margin87.4%
Operating margin12.7%
Net margin-1.8%
FCF margin—
EBITDA margin13.1%
Returns
ROE-27.1%
ROA-1.6%
ROIC (approx.)31.5%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets88.5%
Debt / equity3.89x
Current ratio2.15x
Interest coverage1.70x
Cash quality & payout
Operating cash flow / net income-11.34x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $291.85M | $203.07M |
| Cost of revenue | $42.57M | $36.83M |
| Gross profit | $249.28M | $166.24M |
| R&D expense | $31.16M | $25.56M |
| SG&A expense | $182.37M | $163.48M |
| Operating income | $24.90M | -$33.65M |
| Interest expense | $29.08M | $30.48M |
| Pretax income | $554,000 | -$57.10M |
| Income tax | $0 | -$2.27M |
| Net income | $554,000 | -$54.84M |
| EBITDA | $26.21M | -$32.42M |
| EPS (basic) | 0.00 | -0.37 |
| EPS (diluted) | 0.00 | -0.37 |
| Weighted avg. shares (diluted) | 172.74M | 146.77M |
| Balance sheet | ||
| Cash & equivalents | $111.04M | $75.74M |
| Short-term investments | — | $0 |
| Receivables | $51.05M | $40.41M |
| Inventory | $68.67M | $48.17M |
| Current assets | $240.31M | $167.66M |
| PP&E, net | $4.95M | $5.56M |
| Goodwill | $22.86M | $22.86M |
| Intangibles | $88.08M | $98.92M |
| Total assets | $383.53M | $323.06M |
| Current liabilities | $109.57M | $100.44M |
| Short-term debt | $0 | $15.10M |
| Long-term debt | $220.34M | $217.01M |
| Total debt | $220.34M | $232.11M |
| Total liabilities | $369.84M | $352.68M |
| Shareholders' equity | $13.69M | -$29.61M |
| Net debt | $109.29M | $156.36M |
| Shares outstanding | 166.22M | 149.43M |
| Cash flow statement | ||
| Operating cash flow | $28.63M | -$36.98M |
| Investing cash flow | -$696,000 | $4.88M |
| Financing cash flow | $11.39M | $36.17M |
| Depreciation & amortization | $1.31M | $1.23M |
| Stock-based compensation | $22.37M | $18.36M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.